Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammation01:38

Inflammation

54.6K
Overview
54.6K
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

44
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
44
T Cell Types and Functions01:24

T Cell Types and Functions

1.3K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.3K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

24
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
24
Inflammatory Response01:28

Inflammatory Response

5.2K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
5.2K
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

25
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
25

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

CORRIGENDUM: MicroRNA-182 Promotes Lipoprotein Lipase Expression and Atherogenesisby Targeting Histone Deacetylase 9 in Apolipoprotein E-Knockout Mice.

Circulation journal : official journal of the Japanese Circulation Society·2022
Same author

MicroRNA-134 Promotes the Development of Atherosclerosis Via the ANGPTL4/LPL Pathway in Apolipoprotein E Knockout Mice.

Journal of atherosclerosis and thrombosis·2017
Same author

MicroRNA-182 Promotes Lipoprotein Lipase Expression and Atherogenesisby Targeting Histone Deacetylase 9 in Apolipoprotein E-Knockout Mice.

Circulation journal : official journal of the Japanese Circulation Society·2017
Same author

Advanced oxidation protein products exacerbates lipid accumulation and atherosclerosis through downregulation of ATP-binding cassette transporter A1 and G1 expression in apolipoprotein E knockout mice.

Circulation journal : official journal of the Japanese Circulation Society·2014
Same author

MicroRNA-590 attenuates lipid accumulation and pro-inflammatory cytokine secretion by targeting lipoprotein lipase gene in human THP-1 macrophages.

Biochimie·2014
Same author

MicroRNA-19b promotes macrophage cholesterol accumulation and aortic atherosclerosis by targeting ATP-binding cassette transporter A1.

Atherosclerosis·2014

Related Experiment Video

Updated: Aug 27, 2025

Flow Cytometry Analysis of Immune Cells Within Murine Aortas
15:15

Flow Cytometry Analysis of Immune Cells Within Murine Aortas

Published on: July 1, 2011

34.8K

Interleukin-38 in atherosclerosis.

Xiao-Hong Zhang1, Yu Li2, Li Zhou3

  • 1Department of Cardiovascular Medicine, The Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan 421001, China.

Clinica Chimica Acta; International Journal of Clinical Chemistry
|September 23, 2022
PubMed
Summary

Interleukin-38 (IL-38) combats atherosclerosis by reducing inflammation and cardiovascular disease risk. This immune modulator offers potential for preventing and treating this chronic inflammatory condition.

Keywords:
AtherosclerosisHyperlipidemiaInflammationMacrophagesTh17 cellsTregsinterleukin-38

More Related Videos

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology
05:51

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology

Published on: May 6, 2014

13.3K
Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
09:06

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice

Published on: February 20, 2019

8.4K

Related Experiment Videos

Last Updated: Aug 27, 2025

Flow Cytometry Analysis of Immune Cells Within Murine Aortas
15:15

Flow Cytometry Analysis of Immune Cells Within Murine Aortas

Published on: July 1, 2011

34.8K
A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology
05:51

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology

Published on: May 6, 2014

13.3K
Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice
09:06

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice

Published on: February 20, 2019

8.4K

Area of Science:

  • Immunology
  • Cardiovascular Science
  • Molecular Biology

Background:

  • Atherosclerosis is characterized by chronic inflammation driven by immune cells and mediators.
  • Interleukin-38 (IL-38), an IL-1 family member, possesses anti-inflammatory properties through receptor interactions.
  • IL-38 is known to inhibit key inflammatory signaling pathways like MAPK and NF-κB.

Purpose of the Study:

  • To elucidate the critical role of IL-38 in atherosclerosis development.
  • To provide a theoretical foundation for advanced IL-38 research.
  • To offer insights into atherosclerosis prophylaxis and treatment strategies.

Main Methods:

  • Review of existing literature on IL-38's anti-inflammatory and anti-atherosclerotic mechanisms.
  • Analysis of IL-38's effects on immune regulation, neovascularization, and apoptosis.
  • Examination of IL-38's impact on metabolic factors like obesity, hyperlipidemia, and insulin resistance.

Main Results:

  • IL-38 demonstrates anti-atherosclerotic effects, reducing cardiovascular event risk.
  • IL-38 modulates innate and adaptive immunity, inhibiting inflammation, pathological neovascularization, and apoptosis.
  • IL-38 mitigates obesity, hyperlipidemia, and insulin resistance, contributing to cardiovascular disease risk reduction.

Conclusions:

  • IL-38 plays a vital role in inhibiting atherosclerosis progression.
  • Targeting IL-38 presents a promising therapeutic avenue for cardiovascular disease.
  • Further research into IL-38 mechanisms can enhance atherosclerosis prevention and treatment.